Abstracts Archive - Page 116 of 2607 - ACR Meeting Abstracts

Abstract Number: 1022 • ACR Convergence 2025
Abuse in Rheumatic Diseases: Associations with Depression, Disability, and Psychosocial Risk Factors
Margarita Isabel Alarcon-Jarquin¹, Egla Samantha Sanchez-Peralta², Maria Eugenia Corral-Trujillo³, Daniela Alejandra Salcedo-Soto⁴, Judith Michelle Ramirez-Alonso⁴, Ana Elena González-Rosales⁵, Juan Daniel Valdez-Cruz⁴, Osmel Adrián Ramirez-Uzcategui⁴, Jesús Gilberto Espinoza-Gámez⁶, Yessica Rubi Reyes-Yepiz¹⁴, Juan Pablo González-Morales⁴, Virginia Pascual-Ramos⁷, Dionicio A. Galarza-Delgado⁸, Gabriel Figueroa-Parra⁹ and Diana E. Flores-Alvarado², ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ³Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., Monterrey, Nuevo Leon, Mexico, ⁴Hospital universitario José Eleuterio González, Monterrey, Nuevo Leon, Mexico, ⁵Hospital universitario José Eleuterio González, Monterrey, Mexico, ⁶Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ⁷Rheumatology Service, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico, Mexico City, Distrito Federal, Mexico, ⁸Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁹Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
Background/Purpose: Exposure to a hostile environment may negatively impact disease outcomes in patients with RD, particularly by affecting their mental health and overall quality of…
Abstract Number: 1466 • ACR Convergence 2025
Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Walter P. Maksymowych¹, Robert G. W. Lambert², Victoria Navarro-Compan³, Xenofon Baraliakos⁴, Jason Coarse⁵, Natasha de Peyrecave⁶ and Mikkel Ostergaard⁷, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB, Morrisville, NC, ⁶UCB, Brussels, Belgium, ⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Spinal inflammation and structural progression are key features of radiographic axial spondyloarthritis (r-axSpA).1 Canada-Denmark (CANDEN) scoring enables anatomical-based assessments of MRI inflammatory and structural…
Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Alina-Lucica Boteanu¹, Clara Udaondo², Joan Calzada³, Daniel Clemente Garulo⁴, Juan Carlos Nieto Gonzáles⁵, Eugenia Enriquez⁶, inmaculada Calvo Penades⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, isabel Patora Granados bautista²⁴, Clara Moriano²⁵, Diego Dios¹⁷, Lorena Exposito²⁶, Alicia Garcia²⁷, Laura Martin²⁸, David Fernandez²⁹, Laura Trujillo¹⁴, Anahy Maria Brandy³⁰ and CARLOS GUILLEN-ASTETE³¹, ¹H.U. Ramón y Cajal, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital Sant Joan de Deu, Barcelona, Spain, ⁴H.U Niño Jesús, Madrid, Spain, ⁵H.U Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴H.U Toledo, Toledo, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶H.U Canarias, Canarias, Spain, ²⁷Rheumatologist, La Laguna, Spain, ²⁸H.R.U Malaga, Malaga, Spain, ²⁹Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³⁰Hospital Germans Trias i Pujol, Badalona, Spain, ³¹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…
Abstract Number: 1471 • ACR Convergence 2025
Prevalence and Clinical Outcomes of Hemophagocytic Lymphohistiocytosis in Systemic Lupus Erythematosus: A Multi-Institutional Cohort Study
Amir Daneshvar¹, Julia Wajsberg¹, Chelsea Guan¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker², Meghan Gump¹ and Omer Pamuk³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement. A rare but life-threatening hyper-inflammatory hematological complication of SLE is hemophagocytic lymphohistiocytosis…
Abstract Number: 1475 • ACR Convergence 2025
Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus
Arielle Mendel¹, Maximilien Lora², Sasha Bernatsky³, Paul Fortin⁴, Michaël Desjardins⁵, Joyce Rauch⁶, Chantal Sauvageau⁷, Evelyne Vinet³ and Ines Colmegna⁸, ¹McGill University Health Centre, Montreal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵Centre Hospitalier de l'Université de Montréal (CHUM)), Montreal, QC, Canada, ⁶McGill University, Hampstead, Canada, ⁷Institut national de santé publique du Québec, Quebec City, QC, Canada, ⁸The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for herpes zoster (HZ) and its complications. Exposure to immunosuppressants (IS) at the time…
Abstract Number: 1463 • ACR Convergence 2025
Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Weibin Bao⁹ and Karl Gaffney¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab, an IL-17A inhibitor, has well-established effectiveness in the treatment of psoriasis (PsO) and psoriatic arthritis (PsA) in both long-term clinical trials and the…
Abstract Number: 1400 • ACR Convergence 2025
Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
Renata Fróes Ramos de Lima¹, Regis Sewa Marques², Zoraida Sachetto³ and Alisson Pugliesi⁴, ¹Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil, ²Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil, ³UNIVERSIDADE ESTADUAL DE CAMPINAS, UNICAMP, Campinas, Sao Paulo, Brazil, ⁴Unicamp, Campinas, Brazil
Background/Purpose: Sjogren’s disease (SjD) is a systemic autoimmune disorder characterized by inflammatory involvement of the exocrine glands and extra-glandular manifestations. Among the latter, there is…
Abstract Number: 1414 • ACR Convergence 2025
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Eugeniu Russu¹, Victor Cazac², Mircea Betiu³, Alesea Nistor³ and Liliana Groppa⁴, ¹"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova, ²Norwalk Hospital, Nuvance Health, Connecticut, ³State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Chisinau, Moldova, ⁴State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops in ~20-30% of psoriasis patients. However, early PsA diagnosis is challenging due to heterogeneous, subtle symptoms and overlap with psoriasis…
Abstract Number: 1284 • ACR Convergence 2025
Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
Daniel Clemente¹, Alina-Lucica Boteanu², Clara Udaondo³, Joan Calzada⁴, Juan Carlos Nieto⁵, Eugenia Enriquez⁶, Inmaculada Calvo⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, Clara Moriano²⁴, Diego Dios¹⁷, Lorena Exposito²⁵, Alicia Garcia²⁶, Laura Martin²⁷, David Fernandez²⁸, Laura Trujillo¹⁴, Anahy Maria Brandy²⁹, CARLOS GUILLEN-ASTETE³⁰ and lydia Abasolo Alcazar³¹, ¹Hospital Infantil Universitario NIño Jesús, Madrid, Madrid, Spain, ²H.U. Ramón y Cajal, Madrid, Spain, ³La Paz University Hospital, Madrid, Spain, ⁴University Hospital Sant Joan de Deu, Barcelona, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Hospital La Fe, Valencia, Comunidad Valenciana, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴Hospital León, LEON, Castilla y Leon, Spain, ²⁵H.U Canarias, Canarias, Spain, ²⁶Rheumatologist, La Laguna, Spain, ²⁷H.R.U Malaga, Malaga, Spain, ²⁸Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ²⁹Hospital Germans Trias i Pujol, Badalona, Spain, ³⁰H.U Ramón y Cajal, Madrid, Spain, ³¹IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in juvenile-onset systemic lupus erythematosus (jSLE) patients. We aimed to assess the…
Abstract Number: 1446 • ACR Convergence 2025
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
José Miguel Senabre¹, Lucia Otero², Jerusalén Calvo³, Vega Jovaní⁴, Javier Manero-Ruiz⁵, Rabadán Elena⁶, Eugenia Enriquez⁷, Yanira Pérez⁸, Alicia Garcia⁹, Francisca Sivera¹⁰, Olga Martínez¹¹, María Colazo Burlato¹², Diana Sueiro¹³, Fernando Sánchez-Alonso¹⁴ and Isabel Castrejón Fernández¹⁵, ¹Hospital Marina Baixa, Villajoyosa/Vila Joiosa, La, Comunidad Valenciana, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ⁵Hospital Miguel Servet, Zaragoza, Spain, ⁶Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ⁷Clínica Universidad de Navarra, Madrid, Spain, ⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ⁹Rheumatologist, La Laguna, Spain, ¹⁰Hospital General Universitario Elda, Elda, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ¹²Hospital Universitario de Burgos, Burgos, Spain, ¹³Complexo Hospitalario Universitario de Ourense, Ourense, ¹⁴Sociedad Española de Reumatología, Madrid, Spain, ¹⁵MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Failure of a first-line anti-TNF in axial spondyloarthritis (axSpA) is common, and when it occurs, there are no randomized clinical trials (RCTs) comparing the…
Abstract Number: 1490 • ACR Convergence 2025
Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
judith hernández-Sánchez¹, Beatriz Tejera Segura², Luis Bausá Gimeno¹, Doryan García Olivas¹, Patricia González Terrats¹, MA Acosta Mérida¹, Diana Botello Corzo¹, Daniel Batista perdomo¹, Sergio Machin González¹, F Javier Nóvoa Medina¹ and Jose Angel Hernandez³, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ²Hospital Insular de Gran Canaria, Las palmas, Spain, ³Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs. Vitamin D levels have been associated with disease activity in…
Abstract Number: 1049 • ACR Convergence 2025
Provider Characteristics and Beliefs and Patient Factors Associated with Long-term Glucocorticoid Use in Patients with Rheumatoid Arthritis
Michael George¹, George Reed², Kevin Kane³, Dimitrios Pappas⁴ and Joel Kremer⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Massachusetts Lowell, Lowell, MA, ⁴CorEvitas, New York, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Guidelines recommend limiting glucocorticoid (GC) use in RA, but 30% of patients continue long-term GCs. Little is known about the influence of provider attitudes…
Abstract Number: 1424 • ACR Convergence 2025
Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
Mohamad Bittar¹, Yvonne Lee², Atul Deodhar³, Jennifer Barton⁴ and Alexander Stevens¹, ¹Oregon Health & Science University, Portland, OR, ²Northwestern University, Chicago, IL, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴VA Portland Health Care System/OHSU, Portland, OR
Background/Purpose: Chronic pain is one of the common causes of disability in axial spondyloarthritis (axSpA). The mechanism behind this pain is not well understood, hindering…
Abstract Number: 1425 • ACR Convergence 2025
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Pankti Mehta¹, Shangyi Gao², Virginia Carrizo Abarza³, Fadi Kharouf⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) significantly affects physical function (PF), which is influenced by both disease activity and structural damage. Despite its clinical importance, there is…
Abstract Number: 1314 • ACR Convergence 2025
Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis
Julia King¹, Michael Duryee¹, Punyasha Roul², Katherine Wysham³, Grant Cannon⁴, Gary Kunkel⁵, John Richards⁶, Isaac Smith⁷, Beth Wallace⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Wenxian Zhou¹³, Joshua Baker¹⁴, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Duke University Hospital, Durham, NC, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Nebraska Medical Center, Bellevue, NE, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in rheumatoid arthritis (RA), driven primarily by atherosclerotic CVD (ASCVD) and heart failure (HF). Malondialdehyde-acetaldehyde…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].